Based on our research results and the above literature studies, we believe that HR-positive and/or HER2-positive breast cancer patients could benefit from treatment with PI3K inhibitors (alpelisib and buparlisib), especially in postmenopausal women with endocrine therapy, and the specific mechanism needs to be further researched. This evidence concerns the gene ERBB2 and breast carcinoma.